Aptinyx Inc (APTX) Receives $18.80 Average Price Target from Analysts

Share on StockTwits

Shares of Aptinyx Inc (NASDAQ:APTX) have been given an average rating of “Buy” by the six research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $18.80.

A number of equities research analysts recently commented on APTX shares. Cantor Fitzgerald restated a “buy” rating and set a $40.00 price target on shares of Aptinyx in a research report on Wednesday, January 16th. BMO Capital Markets decreased their price target on Aptinyx to $18.00 and set an “outperform” rating on the stock in a research report on Friday, January 18th. JPMorgan Chase & Co. lowered Aptinyx from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $30.00 to $8.00 in a research report on Thursday, January 17th. Leerink Swann reduced their price objective on Aptinyx from $35.00 to $22.00 and set an “outperform” rating on the stock in a report on Thursday, January 17th. Finally, Zacks Investment Research raised Aptinyx from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a report on Monday, January 21st.

NASDAQ APTX opened at $4.06 on Tuesday. Aptinyx has a one year low of $4.04 and a one year high of $32.25.

In other news, Director Robert J. Hombach acquired 25,000 shares of Aptinyx stock in a transaction on Friday, January 25th. The shares were purchased at an average price of $5.53 per share, with a total value of $138,250.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Ashish Khanna acquired 10,000 shares of Aptinyx stock in a transaction on Friday, January 18th. The shares were purchased at an average cost of $5.45 per share, for a total transaction of $54,500.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 36,050 shares of company stock worth $198,284.

Large investors have recently bought and sold shares of the business. Great West Life Assurance Co. Can acquired a new position in Aptinyx during the 4th quarter worth $40,000. Legal & General Group Plc acquired a new position in shares of Aptinyx in the 3rd quarter valued at $58,000. Strs Ohio acquired a new position in shares of Aptinyx in the 3rd quarter valued at $110,000. Metropolitan Life Insurance Co. NY lifted its stake in shares of Aptinyx by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock valued at $120,000 after purchasing an additional 5,652 shares during the period. Finally, Barclays PLC lifted its stake in shares of Aptinyx by 87.1% in the 4th quarter. Barclays PLC now owns 9,323 shares of the company’s stock valued at $154,000 after purchasing an additional 4,340 shares during the period. 63.11% of the stock is currently owned by hedge funds and other institutional investors.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Featured Story: Why are percentage gainers important?

Analyst Recommendations for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

LGL Group Inc  CEO Michael J. Ferrantino Sells 10,100 Shares
LGL Group Inc CEO Michael J. Ferrantino Sells 10,100 Shares
Snap Inc  CAO Sells $11,998.47 in Stock
Snap Inc CAO Sells $11,998.47 in Stock
Evolus  PT Set at $31.00 by Mizuho
Evolus PT Set at $31.00 by Mizuho
Unification  Price Hits $0.0362 on Exchanges
Unification Price Hits $0.0362 on Exchanges
DaTa eXchange  Trading Up 11% This Week
DaTa eXchange Trading Up 11% This Week
Booking  Research Coverage Started at Needham & Company LLC
Booking Research Coverage Started at Needham & Company LLC


© 2006-2019 Ticker Report